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Table 1a TNM categoris of vulvar cancer
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ (preinvasive carcinoma), intraepithelial neoplasia grade III (VIN III)
T1 Tumour confined to vulva or vulva and perineum
T1a Tumour 2 cm or less in greatest dimension and with stromal invasion no greater than 1.0 mma
T1b Tumour greater than 2 cm and or with stromal invasion greater than 1 mma
T2 Tumour invades any of the following structures: lower third urethra, lower third vagina, anus
T3b Tumour invades any of the following perineal structures: upper 2/3 urethra, upper 2/3 vagina, bladder mucosa, rectal
mucosa; or fixed to pelvic bone
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis with the following features:
N1a One or two lymph node metastasis each less than 5 mm
N1b One lymph node metastases 5 mm or greater
N2 Regional lymph node metastasis with the following features:
N2a Three or more lymph node metastases each less than 5 mm
N2b Two or more lymph node metastases 5 mm or greater
N2c Lymph node metastasis with extracapsular spread
N3 Fixed or ulcerated regional lymph node metastasis
M-Distant Metastasis
M0 No distant metastasis
M1  Distant metastasis (including pelvic lymph node metastasis)
Notes a The depth of invasion is defined as the measurement of the tumour from the epithelial‒
stromal junction of the adjacent most superficial dermal papilla to the deepest point of
invasion.
b T3 is not used by FIGO
Table 1b Stages of vulvar cancer
FIGO Stages T N M
0 Tis N0 M0
I T1 N0 M0 I T1 N0 M0
IA T1a N0 M0 IA T1a N0 M0
IB T1b N0 M0 IB T1b N0 M0
II T2 N0 M0 II T2 N0 M0
IIIA T1, T2 N1a, N1b M0 IIIA(i) T1, T2 N1a M0
IIIA(ii) T1, T2 N1b M0
IIIB T1, T2 N2a, N2b M0 IIIB(i) T1, T2 N2a M0
IIIB(ii) T1, T2 N2b M0
IIIC T1, T2 N2c M0 IIIC T1, T2 N2c M0
IVA T1, T2 N3 M0 IVA T1, T2 N3 M0
T3 Any N M0 T3 Any N M0
IVB Any T Any N M1 IVB Any T Any N M1
FIGO no longer includes Stage 0 (Tis)
Anatomic Stage/TNM Categores
Table 1c Prognostic risk factors for vulvar cancer
Prognostic
factors
Tumour related Host related Environment related
Essential Lymph node
metastases:
· Number
· Size
· Extracapsular tumour
growth
Experience of treating
centre/concentration of care for
vulvar cancer patients in tertiary
referral centres
Additional FIGO stage
Depth of invasion
Diameter of primary
tumour Histological
type
Age
Smoking
Adjacent dermatosis (LS,
VIN) Immune Status
Surgical margins
New and
promising
EGFR status
p53 over expression
P16INK4a level
Microvessel density
HPV status
Pretreatment
haemoglobin
level
Table 2a TNM categoris of vaginal cancer
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ (preinvasive carcinoma)
T1 Tumour confined to vagina
T2 Tumour invades paravaginal tissues (paracolpium)
T3 Tumour extends to pelvic wall
T4 Tumour invades mucosa of bladder or rectum, or extends
beyond the true pelvis*
N-Regional Lymph Nodes
Regional Lymph Nodes
Upper two thirds of vagina: the pelvic nodes including obturator, internal iliac
(hypogastric), external iliac, and pelvic nodes, NOS.
Lower third of vagina: the inguinal and femoral nodes.
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M0 No distant metastasis
M1  Distant metastasis (including pelvic lymph node metastasis)
Note * The presence of bullous oedema is not sufficient evidence to classify a tumour as T4.
Table 2b Stages of vaginal cancer
FIGO Stages T N M
0 Tis N0 M0
I T1 N0 M0 I T1 Tumour confined to vagina
II T2 N0 M0 II T2 Tumour invades paravaginal tissues (paracolpium)
III T3 N0 M0 III T3 Tumour extends to pelvic wall
T1, T2, T3 N1 M0
IVA T4 Any N M0 IVA T4 M0 Tumour invades mucosa of bladder or rectum, or extends
beyond the true pelvis*
IVB Any T Any N M1 IVB M1 Distant metastasis
FIGO no longer includes Stage 0 (Tis)
Anatomic Stage/TNM Categores
Table 3a TNM categoris of cervical cancer
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ (preinvasive carcinoma), intraepithelial neoplasia grade III (VIN III)
T1 Tumour confined to the cervixa
T1abc Invasive carcinoma diagnosed only by microscopy. Stromal invasio with a maximal depth of
5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or
lessd
T1a1 Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread
T1a2 Measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal
spread of 7.0 mm or less
T1b Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2
T1b1 Clinically visible lesion 4.0 cm or less in greatest dimension
T1b2 Clinically visible lesion more than 4.0 cm in greatest dimension
T2 Tumour invades beyond uterus but not to pelvic wall or to lower third of vagina
T2a Tumour without parametrial invasion
T2a1 Clinically visible lesion 4.0 cm or less in greatest dimension
T2a2 Clinically visible lesion more than 4.0 cm in greatest dimension
T2b Tumour with parametrial invasion
T3 Tumour, involves lower third of vagina, or extends to pelvic wall, or
causes hydronephrosis or non functioning kidney
T3a Tumour involves lower third of vagina
T3b Tumour extends to pelvic wall, or causes hydronephrosis or non functioning kidney
T4 Tumour invades mucosa of the bladder or rectum, or extends beyond true pelvise
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis with the following features:
Regional Lymph Nodes
The regional lymph nodes are the paracervical, parametrial, hypogastric (internal iliac,
obturator), common and external iliac, presacral, and lateral sacral nodes. Para aortic
nodes are not regional.
* No FIGO equivalent.
M0 No distant metastasis
M1  Distant metastasis (includes inguinal lymph nodes and intraperitoneal disease). It
excludes metastasis to vagina, pelvic serosa, and adnexa
Notes a Extension to corpus uteri should be disregarded.
b The depth of invasion should be taken from the base of the epithelium, either surface or
glandular, from which it originates. The depth of invasion is defined as the measurement of
the tumour from the epithelial‒stromal junction of the adjacent most measurement of the
tumour from the epithelial‒stromal junction of the adjacent most superficial papillae to the
deepest point of invasion.
Vascular space involvement, venous or lymphatic, does not affect classification.
c All macroscopically visible lesions even with superficial invasion are T1b/IB.
d Vascular space involvement, venous or lymphatic, does not affect classification.
e Bullous oedema is not sufficient to classify a tumour as T4.
Table 3b Stages of cervical cancer
Anatomic Stage/TNM Categores FIGO Stages T M
O Tis N0 M0
I T1 N0 M0 I T1 M0
IA T1a N0 M0 IA T1a M0
IA1 T1a1 N0 M0 IA1 T1a1 M0
IA2 T1a2 N0 M0 IA2 T1a2 M0
IB T1b N0 M0 IB T1b M0
IB1 T1b1 N0 M0 IB1 T1b1 M0
IB2 T1b2 N0 M0 IB2 T1b2 M0
II T2 N0 M0 II T2 M0
IIA T2a N0 M0 IIA T2a M0
IIA1 T2a1 N0 M0 IIA1 T2a1 M0
IIA2 T2a2 N0 M0 IIA2 T2a2 M0
IIB T2b N0 M0 IIB T2b M0
III T3 N0 M0 III T3 M0
IIIA T3a N0 M0 IIIA T3a M0
IIIB T3b Any N M0 IIIB T3b M0
T1, T2, T3 N1 M0
IVA T4 Any N M0 IVA T4 M0
IVB Any T Any N M1 IVB M1
Table 3c Prognostic risk factors for cervical cancer
Prognostic
factors
Tumour related Host related Environment related
Essential Unilateral vs bilateral
disease
Parametrial invasion
Invasion to side wall
Size of tumour
Lymph node invasion
Positive surgical margins
Immunosuppression
(i.e. HIV infection)
Performance status
Morbid obesity
Quality of and
availability of
anticancer therapies
Expertise of healthcare
personnel
Multidisciplinary teams
Additional Lymphovascular space
invasion Histological type
Anaemia during
treatment
Ability to manage co
morbid conditions
New and
promising
Tumour hypoxia
VEGF, mEGFR, HIF 1α, COX
2 PAI 1 expression
SCC Ag and hsCRP for early
detection of recurrence
Serum MyoDI
hypermethylation
Persistence of HPV
infection following
treatment
Adequate laboratory
facilities to measure
tumour markers
Table 4a TNM categoris of endometrial cancer
TNM categories FIGO Stage
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour confined to the corpus uteria Ia
T1a Tumour limited to endometrium or invading less than half of
myometrium
IAa
T1b Tumour invades one half or more of myometrium IB
T2 Tumour invades cervical stroma, but does not extend beyond the
uterus
II
T3 Local and/or regional spread as specified here: III
T3a Tumour invades the serosa of the corpus uteri or adnexae (direct
extension or metastasis)
IIIA
T3b Vaginal or parametrial involvement (direct extension or
metastasis)
IIIB
N1, N2 Metastasis to pelvic or para aortic lymph nodesb IIIC
N1 Metastasis to pelvic lymph nodes IIIC1
N2 Metastastis to para aortic lymph nodes with or without
metastasis to pelvic lymph nodes
IIIC2
T4c Tumour invades bladder/bowel mucosa IV
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis to pelvic lymph nodes
N2 Regional lymph node metastasis to para aortic lymph nodes with or
without
metastasis to pelvic lymph nodes
M0 No distant metastasis
M1 Distant metastasis (excluding metastasis to vagina, pelvic serosa, or
adnexa,
including metastasis to inguinal lymph nodes, intra abdominal lymph
nodes other
than para aortic or pelvic nodes)
Notes a Endocervical glandular involvement only should be considered as
stage I.
b TPositive cytology has to be reported separately without changing
the stage.
c The presence of bullous oedema is not sufficient evidence to classify
as T4.
Table 4b Stages of endometrial cancer
Anatomic Stage/TNM Categores FIGO Stages T M
O Tis N0 M0
I T1 N0 M0 Ia T1 N0 M0
IA T1a N0 M0 IAa T1a N0 M0
IB T1b N0 M0 IB T1b N0 M0
II T2 N0 M0 II T2 N0 M0
IIIA T3a N0 M0 IIIA T3a N0 M0
IIIB T3b Any N M0 IIIB T3b N0 M0
III T1, T2, T3 N1, N2 M0 IIIC N1, N2
IIIC1 T1, T2, T3 N1 M0 IIIC1 N1
IIIC2 T1, T2, T3 N2 M0 IIIC2 N2
IVA T4 Any N M0 IVA T4 M0
IVB Any T Any N M1 IVB M1
Table 4c Prognostic risk factors for endometrial cancer
Prognostic
factors
Tumour related Host related Environment
related
Essential Depth of myometrial
invasion
Grade of differentiation
Tumour cell
type Lymphovascular
space invasion
Postsurgical
treatment
Additional Metastasis to lymph
nodes
Site of distant metastasis
Age
Performance
status
Race
Comorbidities
Extent of resection
Postsurgical
treatment
New and
promising
Molecular profile
Table 4d TNM categories of leiomyosarcoma and endometral stromal sarcoma
TNM Categories FIGO Stages Difinition
T1 I Tumour limited to the uterus
T1a IA Tumour 5 cm or less in greatest dimension
T1b IB Tumour more than 5 cm
T2 II Tumour extends beyond the uterus, within the pelvis
T2a IIA Tumour involves adnexa
T2b IIB Tumour involves other pelvic tissues
T3 III Tumour infiltrates abdominal tissues
T3a IIIA One site
T3b IIIB More than one site
N1 IIIC Metastasis to regional lymph nodes
T4 IVA Tumour invades bladder or rectum
M1 IVB Distant metastasis
Note Simultaneous tumours of the uterine corpus and ovary/pelvis in
association with
ovarian/pelvic endometriosis should be classified as independent
primary tumours.
Table 4e TNM categories of adenosarcoma
TNM Categories FIGO Stages Difinition
T1 I Tumour limited to the uterus
T1a IA Tumour limited to the
endometrium/endocervix
T1b IB Tumour invades to less than half of the
myometrium
T1c IC Tumour invades more than half of the
myometrium
T2 II Tumour extends beyond the uterus,
within the pelvis
T2a IIA Tumour involves adnexa
T2b IIB Tumour involves other pelvic tissues
T3 III Tumour infiltrates abdominal tissues
T3a IIIA One site
T3b IIIB More than one site
N1 IIIC Metastasis to regional lymph nodes
T4 IVA Tumour invades bladder or rectum
M1 IVB Distant metastasis
Table 4f Stages of Uterine Sarcomas
I T1 N0 M0
IA T1a N0 M0
IB T1b N0 M0
IC* T1c N0 M0
II T2 N0 M0
IIA T2a N0 M0
IIB T2b N0 M0
IIIA T3a N0 M0
IIIB T3b N0 M0
IIIC T1, T2, T3 N1 M0
IVA T4 Any N M0
IVB Any T Any N M1
Note *Stage IC does not apply for
leiomyosarcoma and endometrial
stromal sarcoma.
TNM Categories FIGO Stages Difinition
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 I Tumour limited to the ovaries (one or both) or fallopian
tube(s)
  T1a   IA Tumour limited to one ovary; capsule intact, no tumour on
ovarian surface or fallopian tube surface; no malignant cells in
ascites or peritoneal washings
  T1b   IB Tumour limited to both ovaries or fallopian tubes; capsule
intact, no tumour on ovarian or fallopian tube surface; no
malignant cells in ascites or peritoneal washings
  T1c   IC Tumour limited to one or both ovaries or fallopian tubes with
any of the following:
  T1c1 Surgical spill
  T1c2 Capsule ruptured before surgery or tumour on ovarian or
fallopian tube surface
  T1c3 Malignant cells in ascites or peritoneal washings
T2 II Tumour involves one or both ovaries or fallopian tubes with
pelvic extension (below the pelvic brim) or primary peritoneal
cancer
  T2a   IIA Extension and/or implants on uterus and/or fallopian tube(s)
and or ovary(ies)
  T2b   IIB Extension to other pelvic tissues, including bowel within the
pelvis
T3 and/ or N1 IIIa Tumour involves one or both ovaries or fallopian tubes or
primary peritoneal carcinoma with cytologically or
histologically confirmed spread to the peritoneum outside the
pelvis and/or metastasis to the retroperitoneal lymph nodes
N1 Retroperitoneal lymph node metastasis only
  N1a   IIIA1i Lymph node metastasis not more than 10 mm in greatest
dimension
  N1b   IIIA1ii Lymph node metastasis more than 10 mm in greatest
dimension
  T3a any N   IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal
involvement with or without retroperitoneal lymph node,
including bowel involvement
  T3b any N   IIIB Macroscopic peritoneal metastasis beyond pelvic brim 2 cm, or
less in greatest dimension, including bowel involvement
outside the pelvis with or without retroperitoneal nodes
  T3c any N   IIIC Peritoneal metastasis beyond pelvic brim more than 2 cm in
greatest dimension and/or retroperitoneal lymph node
metastasis (includes extension of tumour to capsule of liver
and spleen without parenchymal involvement of either organ)
M1 IV Distant metastasis (excludes peritoneal metastasis)
  M1a   IVA Pleural effusion with positive cytology
  M1bb   IVB Parenchymal metastasis and metastasis to extra abdominal
organs (including inguinal lymph nodes and lymph nodes
outside the abdominal cavity)
Notes a Liver capsule metastasis is T3/stage III.
b Liver parenchymal metastasis M1/stage IV.
Table 5a The FIGO stages are based on surgical staging. (TNM stages are based on clinical and/or
Table 5b Prognostic risk factors for  tumors of the Ovary, Fallopian Tube and Peritoneal Carcinoma
Prognostic
factors
Tumour related Host related Environment related
Essential Histological type
Grade
Surgical stage Residual disease
Age
Comorbidities
Performance
status
Maximum diameter
of residual disease
after optimal
debulking
Additional Nodal involvement Site of metastasis
DNA ploidy
CA125
BRCA1
Genetic predisposition
Type of chemotherapy
CA125 fall
Ultra radical surgery
New and
promising
Molecular profile
Cellular proliferative activity
Tumour angiogenesis markers
p53 expression
Expression of human
kallikrein (hK) genes, particularly hKs 6-10-11
Interval debulking surgery (IDS)
Neoadjuvant chemotherapy
Table 6a Stages of gestational trophoblastic tumors
TNM Categories FIGO Stagesa Difinition
TX Primary tumour cannot be assessed
Stage T0 No evidence of primary tumour
I T1 M0 T1 I Tumour confined to uterus
II T2 M0 T2b II
Tumour extends to other genital structures: vagina,
ovary, broad
ligament, fallopian tube by metastasis or direct
extension
III Any T M1a M1a III Metastasis to lung(s)
IV Any T M1b M1bc IV Other distant metastasis
Notes a Stages I to IV are subdivided into A and B according to the prognostic score.
b Genital metastasis (vagina, ovary, broad ligament, fallopian tube) is classified T2.
c Any involvement of non genital structures, whether by direct invasion or metastasis is
described using the M classification.
Table 6b Prognostic Scoring Index for gestational trophoblastic tumors
Prognostic Factor 0 1 2 4
Age <40 >40
Antecedent
pregnancy
Hydatidifor
m mole
Abortion Term
pregnancy
Months from
index pregancy
(months)
<4  4 to 6 7 to 12 >12
Pretreatment
serum hCG
(IU/ml)
<103 103 to 104 104 to 105 >105
Largest tumour
size including
uterus
Lung Spleen,
kidney
Gastrointest
inal tract
Liver, brain
Sites of
metastasis
1 to 4 5 to 8 >8
Previous failed
chemotherapy
Single drug Two or more
drugs
Risk categories
Total prognostic score 6 or less = low risk
Total score 7 or more = high risk
